

Mandana Nikpour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5547131/publications.pdf>

Version: 2024-02-01

82
papers

2,717
citations

185998

28
h-index

197535

49
g-index

82
all docs

82
docs citations

82
times ranked

3112
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1615-1621.	0.5	421
2	Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. <i>Arthritis Research and Therapy</i> , 2011, 13, R211.	1.6	135
3	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1152-1158.	6.7	117
4	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017, 19, 62.	1.6	100
5	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	5.8	100
6	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
7	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 7.	1.6	95
8	Epidemiology of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 857-869.	1.4	90
9	Premature Atherosclerosis in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 329-354.	0.8	82
10	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , 2016, 3, e000157.	1.1	77
11	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R156.	1.6	71
12	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017, 19, 42.	1.6	67
13	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , The, 2019, 1, e95-e102.	2.2	65
14	Mortality in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 131-137.	2.0	59
15	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2013, 15, R193.	1.6	57
16	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2017, 19, 122.	1.6	53
17	Musculoskeletal Manifestations of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 507-518.	0.8	46
18	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 260.	1.6	44

#	ARTICLE	IF	CITATIONS
19	The need to define treatment goals for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014, 10, 567-571.	3.5	43
20	Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 221-239.	1.6	43
21	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
22	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	1.0	36
23	Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. <i>BMC Pulmonary Medicine</i> , 2016, 16, 134.	0.8	35
24	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. <i>Scientific Reports</i> , 2016, 6, 29909.	1.6	35
25	Defining primary systemic sclerosis heart involvement: A scoping literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 874-887.	1.6	35
26	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 248-254.	2.1	34
27	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
28	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 807-816.	0.5	33
29	Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 937-954.	0.6	32
30	Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. <i>Arthritis Research and Therapy</i> , 2019, 21, 299.	1.6	29
31	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R125.	1.6	24
32	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	0.9	24
33	Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 1625-1635.	1.5	24
34	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S131-5.	0.4	24
35	CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. <i>Journal of Autoimmunity</i> , 2018, 88, 131-138.	3.0	23
36	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000372.	1.1	23

#	ARTICLE	IF	CITATIONS
37	Hydroxychloroquine in dermatology: New perspectives on an old drug. <i>Australasian Journal of Dermatology</i> , 2020, 61, e150-e157.	0.4	20
38	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1289-1295.	1.5	19
39	Measures of disease status in systemic sclerosis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 473-487.	1.6	18
40	Clinical Features of Systemic Sclerosisâ€“Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. <i>Arthritis Care and Research</i> , 2021, 73, 732-741.	1.5	18
41	The clinical and economic burden of systemic sclerosis related interstitial lung disease. <i>Rheumatology</i> , 2020, 59, 1878-1888.	0.9	17
42	â€“Not at targetâ€™: prevalence and consequences of inadequate disease control in systemic lupus erythematosusâ€”a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
43	Using discrete choice experiments as a decision aid in total knee arthroplasty: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 416.	0.7	16
44	Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 170-176.	0.4	16
45	A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1728-1750.	0.9	15
46	Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 4752-4762.	0.9	15
47	Highâ€“sensitivity Câ€“reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3052-3053.	6.7	14
48	The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 246.	1.6	12
49	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 495-512.	1.6	12
50	Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 299-309.	1.6	11
51	Systemic sclerosis: The need for structured care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 3-21.	1.4	10
52	Cancer and scleroderma: recent insights. <i>Current Opinion in Rheumatology</i> , 2020, 32, 479-487.	2.0	10
53	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2022, 41, 357-366.	1.0	10
54	The role of inflammatory markers in assessment of disease activity in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 126-134.	0.4	10

#	ARTICLE	IF	CITATIONS
55	Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 188-195.	1.0	9
56	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9
57	How do surgeons trade-off between patient outcomes and risk of complications in total knee arthroplasty? a discrete choice experiment in Australia. <i>BMJ Open</i> , 2019, 9, e029406.	0.8	8
58	Myocardial fibrosis and arrhythmic burden in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 4497-4502.	0.9	8
59	Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 79-84.	0.4	8
60	Systemic sclerosis in adults. Part II: management and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 957-978.	0.6	7
61	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 142-148.	0.4	6
62	Assessment of Coronary Risk Based on Cumulative Exposure to Lipids in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 2006-2014.	1.0	5
63	How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-215650.	0.5	5
64	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. <i>BMC Pulmonary Medicine</i> , 2019, 19, 226.	0.8	5
65	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021, 160, 2158-2162.	0.4	5
66	Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling. <i>Arthritis Care and Research</i> , 2023, 75, 640-647.	1.5	5
67	Performance of the 2017 EUSTAR activity index in an scleroderma cohort. <i>Clinical Rheumatology</i> , 2020, 39, 3701-3705.	1.0	4
68	Correspondence on the clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e33-e33.	0.5	4
69	Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!. <i>European Journal of Rheumatology</i> , 2020, 7, 187-192.	1.3	4
70	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151973.	1.6	4
71	Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival. <i>Arthritis Research and Therapy</i> , 2022, 24, 103.	1.6	4
72	Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to the question "Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?" by Coudrec et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e138-e138.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 130-137.	0.4	2
74	Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 1-2.	1.4	1
75	Gaining the Upper Hand on Systemic Sclerosis Digital Ulcers. <i>Journal of Rheumatology</i> , 2019, 46, 548-549.	1.0	1
76	Response to: "Differentiating disease activity from damage in systemic sclerosis: it's still early days!" by Jain and Sharma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e99-e99.	0.5	1
77	Safety of Intra-articular Corticosteroid Injection. <i>Radiology</i> , 2020, 294, 720-722.	3.6	1
78	Response to: "Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter" by Sbeih et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e149-e149.	0.5	1
79	The Assessment of Disease Activity in Rheumatic Diseases. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-2.	0.9	0
80	Controversies and advances in connective tissue disease-related pulmonary arterial hypertension. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1269-1275.	0.9	0
81	Response to: "Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?" by Chessa et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-217692.	0.5	0
82	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 142-148.	0.4	0